High levels of MDM2 are not correlated with the presence of wild-type p53 in human malignant mesothelioma cell lines

British Journal of Cancer

Volumn 74, Issue 10, 1996, Pages 1534-1540

  Ungar, S ^a   Van De Meeren, A ^b   Tammilehto, L ^c   Linnainmaa, K ^d   Mattson, K ^e   Gerwin, B I ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE IRSN   (France)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^e UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Carcinogenesis; Mesothelioma; Tumour suppressor

Indexed keywords

CELL PROTEIN; ONCOPROTEIN;

ARTICLE; HUMAN; HUMAN CELL; MALIGNANT MESOTHELIOMA; MESOTHELIUM CELL; NULL CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOUTHERN BLOTTING; TUMOR SUPPRESSOR GENE;

EID: 0029952064     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.585     Document Type: Article

References (67)

1. BARAK Y AND OREN M. (1992). Enhanced binding of a 95 kDa protein to p53 in cells undergoing p53-mediated growth arrest. EMBO J., 11, 2115-2121.
2. BARAK Y, JUVEN T, HAFFNER R AND OREN M. (1993). mdm2 expression is induced by wild type p53 activity. EMBO J., 12, 461-468.
3. BARAK Y, GOTTLIEB E, JUVEN-GERSHON T AND OREN M. (1994). Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev., 8, 1739-1749.
4. BARRETT JC. (1991). Role of chromosomal mutations in asbestos-induced cell transformation. In Cellular and Molecular Aspects of Fibre Carcinogenesis. Current Communications in Cell and Molecular Biology 2. Harris CC, Lechner JF and Brinkley BR. (eds). pp. 27-39. Cold Springer Harbor Laboratory Press: New York.
5. BENEDICT WF, XU HJ, HU SX AND TAKAHASHI R. (1990). Role of the retinoblastoma gene in the initiation and progression of human cancer. J. Clin. Invest., 85, 988-993.
6. BUESO-RAMOS CE, YANG Y, DELEON E, MCCOWN P, STASS SA AND ALBITAR M. (1993). The human MDM-2 oncogene is overexpressed in leukemias. Blood, 82, 2617-2623.
7. CAHILLY-SNYDER L, YANG-FENG T, FRANCKE U AND GEORGE DL. (1987). Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat. Cell. Mol. Genet., 13, 235-244.
8. CARBONE M, PASS HI, RIZZO P, MARINETTI M, DI MUZIO M, MEW DJ, LEVINE AS AND PROCOPIO A. (1994). Simian virus 40-like DNA sequences in human pleural mesothelioma. Oncogene, 9, 1781-1790.
9. CHEN J, MARECHAL V AND LEVINE AJ. (1993). Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol., 13, 4107-4114.
10. CHENG JQ, JHANWAR SC, KLEIN WM, BELL DW, LEE WC, ALTOMARE DA, NOBORI T, OLOPADE OI, BUCKLER AJ AND TESTA JR. (1994). p16 alterations and deletion mapping of 9p21 - p22 in malignant mesothelioma. Cancer Res., 54, 5547-5551.
11. CHOMCZYNSKI P AND SACCHI N. (1987). Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162, 156-159.
12. CORDON-CARDO C, LATRES E, DROBNJAK M, OLIVA MR, POLLACK D, WOODRUFF JM, MARECHAL V, CHEN J, BRENNAN MF AND LEVINE AJ. (1994). Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res., 54, 794-799.
13. CRAIGHEAD JE AND MOSSMAN BT. (1982). The pathogenesis of asbestos-associated diseases. N. Engl. J. Med., 306, 1446-1455.
14. DECAPRIO JA, LUDLOW JW, FIGGE J, SHEW JY, HUANG CM, LEE WH, MARSILIO E, PAUCHA E AND LIVINGSTON DM. (1988). SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell, 54, 275-283.
15. DYSON N, HOWLEY PM, MUNGER K AND HARLOW E. (1989). The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science, 243, 934-937.
16. EWEN ME, SLUSS HK, SHERR CJ, MATSUSHIME H, KATO J AND LIVINGSTON DM. (1993). Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell, 73, 487-497.
17. FAKHARZADEH SS, TRUSKO SP AND GEORGE DL. (1991). Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J., 10, 1565-1569.
18. FARMER G, BARGONETTI J, ZHU H, FRIEDMAN P, PRYWES R AND PRIVES C. (1992). Wild-type p53 activates transcription in vitro (see comments). Nature, 358, 83-86.
19. FINLAY CA. (1993). The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol. Cell. Biol., 13, 301-306.
20. FORT P, MARTY L, PIECHACZYK M, EL SABROUTY S, DANI C, JEANTEUR P AND BLANCHARD JM. (1985). Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate-dehydrogenase multigenic family. Nucleic Acids Res., 13, 1431-1442.
21. GOODRICH DW AND LEE WH. (1993). Molecular characterization of the retinoblastoma susceptibility gene. Biochim. Biophys. Acta, 1155, 43-61.
22. GUDAS JM, NGUYEN H, KLEIN RC, KATAYOSE D, SETH P AND COWAN KH. (1995). Differential expression of multiple MDM2 messenger RNAs and proteins in normal ant tumorigenic breast epithelial cells. Clin. Cancer Res., 1, 71-80.
23. HAINES DS, LANDERS JE, ENGLE LJ AND GEORGE DL (1994). Physical and functional interaction between wild-type p53 and mdm2 proteins. Mol. Cell. Biol., 14, 1171-1178.
24. HEI TK, PIAO CQ, HE ZY, VANNAIS D AND WALDREN CA. (1992). Chrysotile fibre is a strong mutagen in mammalian cells. Cancer Res., 52, 6305-6309.
25. HOLLSTEIN M, SIDRANSKY D, VOGELSTEIN B AND HARRIS CC. (1991). p53 mutations in human cancers. Science, 253, 49-53.
26. JIANG D, SRINIVASAN A, LOZANO G AND ROBBINS PD. (1993). SV40 T antigen abrogates p53-mediated transcriptional activity. Oncogene, 8, 2805-2812.
27. KUERBITZ SJ, PLUNKETT BS, WALSH WV AND KASTAN MB. (1992). Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl Acad. Sci. USA, 89, 7491-7495.
28. LADANYI M, CHA C, LEWIS R, JHANWAR SC, HUVOS AG AND HEALEY JH. (1993). MDM2 gene amplification in metastatic osteosarcoma. Cancer Res., 53, 16-18.
29. LANDERS JE, HAINES DS, STRAUSS JF III, AND GEORGE DL (1994). Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene, 9, 2745-2750.
30. LAVECK MA, SOMERS ANA, MOORE LL, GERWIN BI AND LECHNER JF. (1988). Dissimilar peptide growth factors can induce normal human mesothelial cell multiplication. In Vitro, 24, 1077-1084.
31. LEACH FS, TOKINO T, MELTZER P, BURRELL M, OLINER JD, SMITH S, HILL DE, SIDRANSKY D, KINZLER KW AND VOGELSTEIN B. (1993). p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res., 53, 2231-2234.
32. LECHNER JF AND LAVECK MA. (1985). A serum-free method for culturing normal human bronchial epithelial cells at clonal density. J. Tissue Culture Meth., 9, 43-48.
33. LECHNER JF, TOKIWA T, LAVECK MA, BENEDICT WF. BANKS-SCHLEGEL SP, YEAGER H, JR., BANERJEE A AND HARRIS CC. (1985). Asbestos-associated chromosomal changes in human mesothelial cells. Proc. Natl Acad. Sci. USA, 82, 3884-3888.
34. LECHNER JF, LAVECK MA, GERWIN BI AND MATIS EA. (1989). Differential responses to growth factors by normal human mesothelial cultures from individual donors. J. Cell Physiol., 139, 295-300.
35. LEVINE AJ, MOMAND J AND FINLAY CA. (1991). The p53 tumour suppressor gene. Nature, 351, 453-456.
36. LU X AND LANE DP. (1993). Differential induction of transcriptionally active p53 following UV or ionising radiation: defects in chromosome instability syndromes? Cell, 75, 765-778.
37. MANIATIS, FRITSCH EF AND SAMBROOK J. (1982). Molecular Cloning: A Laboratory Manual. Cold Spring Harbour Press: New York.
38. MARCHETTI A, BUTTITTA F, PELLEGRINI S, MERLO G, CHELLA A, ANGELETTI CA AND BEVILACQUA G. (1995). mdm2 gene amplification and overexpression in non-small cell lung carcinomas with accumulation of the p53 protein in the absence of p53 gene mutations. Diagn. Mol. Pathol., 4, 93-97.
39. MARTIN K, TROUCHE D, HAGEMEIER C, SORENSEN TS, LA THANGUE NB AND KOUZARIDES T. (1995). Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature, 375, 691-694.
40. METCALF RA, WELSH JA, BENNETT WP, SEDDON MB, LEHMAN TA, PELIN K, LINNAINMAA K, TAMMILEHTO L, MATTSON K, GERWIN BI AND HARRIS CC. (1992). p53 and Kirsten-ras mutations in human mesothelioma cell lines. Cancer Res., 52, 2610-2615.
41. MIETZ JA, UNGER T, HUIBREGTSE JM AND HOWLEY PM. (1992). The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J., 11, 5013-5020.
42. MOMAND J, ZAMBETTI GP, OLSON DC, GEORGE D AND LEVINE AJ. (1992). The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69, 1237-1245.
43. MOSSMAN BT, MARSH JP AND SHATOS MA. (1986). Alteration of Superoxide dismutase activity in tracheal epithelial cells by asbestos and inhibition of cytotoxicity by antioxidants. Lab. Invest., 54, 204-212.
44. OKAMOTO A, DEMETRICK DJ, SPILLARE EA, HAGIWARA K, HUSSAIN SP, BENNETT WP, FORRESTER K, GERWIN B, SERRANO M, BEACH DH AND HARRIS CC. (1994). Mutations and altered expression of genes upregulating the cell cycle G1 checkpoint in human cancer. Proc. Natl Acad. Sci. USA. 91, 11045-11049.
45. OLINER JD, KINZLER KW, MELTZER PS, GEORGE DL AND VOGELSTEIN B. (1992). Amplification of a gene encoding a p53-associated protein in human sarcomas (see comments). Nature, 358, 80-83.
46. OLSON DC, MARECHAL V, MOMAND J, CHEN J, ROMOCKI C AND LEVINE AJ. (1993). Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. Oncogene. 8, 2353-2360.
47. PERRY ME, PIETTE J, ZAWADZKI JA, HARVEY D AND LEVINE AJ. (1993). The mdm-2 gene is induced in response to LJV light in a p53-dependent manner. Proc. Natl Acad. Sci. USA, 90, 11623-11627.
48. PICKSLEY SM AND LANE DP. (1993). The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53? Bioessays, 15, 689-690.
49. PIETENPOL JA AND VOGELSTEIN B. (1993). Tumour suppressor genes. No room at the p53 inn (news; comment). Nature, 365, 17-18.
50. QUESNEL B, PREUDHOMME C, OSCIER D, LEPELLEY P, COLLYN-D'HOOGHE M, FACON T, ZANDECKI M AND FENAUX P. (1994). Over-expression of the MDM2 gene is found in some cases of haematological malignancies. Br. J. Haematol., 88, 415-418.
51. RAMAEL M, SEGERS K AND VANMARCK E. (1994). Differential immunohistochemical staining for retinoblastoma protein with the antibodies C15 and 1F8 in malignant mesothelioma. Pathol. Res. Pract., 190, 138-141.
52. RAVETCH JV, SIEBENLIST U, KORSMEYER S, WALDMANN T AND LEDER P. (1981). Structure of the human immunoglobulin mu locus: characterization of embryonic and rearranged J and D genes. Cell, 11, 583-591.
53. REIHENBERGER G, LIU L, ICHIMURA K, SCHMIDT EE AND COLLINS VP. (1993). Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res., 53, 2736-2739.
54. SEGERS K, BACKHOVENS H, SINGH SK, DE VOECHT J, RAMAEL M, VAN BROECKHOVEN C AND VAN MARCK E. (1995). Immunoreactivity for p53 and mdm2 and the detection of p53 mutations in human malignant mesothelioma. Virchows. Arch., 427, 431-436.
55. VAN DER MEEREN A, SEDDON MB, KISPERT J, HARRIS CC AND GERWIN BI. (1993). Lack of expression of the retinoblastoma gene is not frequently involved in the genesis of human mesothelioma. Eur. Resp. Rev., 3, 177-179.
56. VOGELSTEIN B AND KINZLER KW. (1992). p53 function and dysfunction. Cell, 70, 523-526.
57. WAGNER JC AND BERRY G. (1969). Mesotheliomas in rats following inoculation with asbestos. Br. J. Cancer, 23, 567-581.
58. WAGNER JC, SLEGGS CA AND MARCHAND P. (1960). Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br. J. Ind. Med., 17, 260-271.
59. WANG XW, VERMEULEN W, COURSEN JD, GIBSON M, LUPOLD SE, FORRESTER K, XU G, ELMORE L, YEH H, HOEIJMAKERS JHJ AND HARRIS CC. (1996). The XPB and XPD helicases are components of the p53-mediated apoptosis pathway. Genes Dev., 10, 1219-1232.
60. WHYTE P, BUCHKOVICH KJ, HOROWITZ JM, FRIEND SH, RAYBUCK M, WEINBERG RA AND HARLOW E. (1988). Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. Nature, 334, 124-129.
61. WU X, BAYLE JH, OLSON D AND LEVINE AJ. (1993). The p53-mdm-2 autoregulatory feedback loop. Genes Dev., 7, 1126-1132.
62. XIAO S, LI D, CORSON JM, VIJG J AND FLETCHER JA. (1995). Codeletion of p15 and p16 genes in primary non-small cell lung carcinoma. Cancer Res., 55, 2968-2971.
63. XIAO ZX, CHEN J, LEVINE AJ, MODJTAHEDI N, XING J, SELLERS WR AND LIVINGSTON DM. (1995). Interaction between the retinoblastoma protein and the oncoprotein M DM2. Nature, 375, 694-698.
64. YEW PR AND BERK AJ. (1992). Inhibition of p53 transactivation required for transformation by adenovirus early IB protein. Nature, 357, 82-85.
65. ZAUBERMAN A, BARAK Y, RAGIMOV N, LEVY N AND OREN M. (1993). Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53 MDM2 complexes. EMBO J., 12, 2799-2808.
66. ZAUBERMAN A, FLUSBERG D, HAUPT Y, BARAK Y AND OREN M. (1995). A functional p53-responsive intronic promoter is contained within the human milm2 gene. Nucleic Acids Res., 23, 2584-2592.
67. ZHOU M, YEAGER AM, SMITH SD AND FINDLEY HW. (1995). Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene. Blood, 85, 1608-1614.